Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques

Journal of Thoracic and Cardiovascular Surgery

Volumn 123, Issue 4, 2002, Pages 686-694

  Schrump, David S ^a   Zhai, Suoping ^a   Nguyen, Dao M ^a   Weiser, Todd S ^a   Fisher, Bradley A ^b   Terrill, Richard E ^b   Flynn, Bernard M ^b   Duray, Paul H ^a   Figg, William D ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; EOSIN; HEMATOXYLIN; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRONCHUS MUCOSA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TISSUE LEVEL; EXTRACORPOREAL CIRCULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; ISOLATED LUNG; LUNG CANCER; LUNG PERFUSION; MAXIMUM TOLERATED DOSE; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL; SHEEP;

EID: 0036095810     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2002.120713     Document Type: Article

References (42)

1. Metastatic cancer to the lung
2. Pulmonary resection for solitary metastatic sarcoma and carcinoma
3. Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases
4. Treatment of the patient with lung metastases
5. Lung perfusion with chemotherapy in patients with unresectable metastatic sarcoma to the lung or diffuse branchioloalveolar carcinoma
6. Isolated lung perfusion for patients with unresectable metastases from sarcoma: A phase I trial
7. Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas
8. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases
9. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice
10. High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma
11. Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin
12. Phase I study of paclitaxel administered as a 1-hour infusion: Toxicity and pharmacokinetics
13. Pharmacologic rationale for regional drug delivery
14. Arterial drug infusion: Pharmacokinetic problems and pitfalls
15. Melphalan resistance and photoaffinity labelling of P-glycoprotein in multidrug-resistant Chinese hamster ovary cells: Reversal of resistance by cyclosporin A and hyperthermia
16. In vitro thermo-chemosensitivity screening of spontaneous human tumors: Significant potentiation for cisplatin but not adriamycin
17. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants
18. Taxol in malignant melanoma
19. Selective isolated perfusion of the right lung
20. Lung perfusion with chemotherapeutic agents
21. The vascular supply to metastatic tumors of the lung
22. Angioarchitecture of pulmonary malignancies in humans
23. Bronchial artery infusion therapy for lung cancer
24. Taxances
25. Difference in cytotoxicity of paclitaxel against neoplastic and normal cells
26. Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together
27. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group study
28. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer
29. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
30. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
31. The pharmacokinetics of a 1-h paclitaxel infusion
32. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment
33. Arterial paclitaxel distribution and deposition
34. Isolated hepatic perfusion for lapine liver metastases: Impact of hyperthermia on permeability of tumor neovasculature
35. Effect of hyperthermia on intracellular drug accumulation and chemosensitivity in drug-sensitive and drug-resistant P388 leukaemia cell lines
36. Lack of thermal enhancement for taxanes in vitro
37. Interaction of hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells
38. Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma
39. Taxol in malignant melanoma
40. Phase II trial of paclitaxel in patients with soft-tissue sarcoma
41. The microtubule-affecting drug paclitaxel has antiangiogenic activity
42. Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer